Brief: Finch Therapeutics Regains Full Rights To FIN-524 And FIN-525 Targeted Microbiome Product Candidates In Development For IBD
25/08/2022 21:35
Aug 25 (Reuters) - Finch Therapeutics Group Inc FNCH.O :
* FINCH THERAPEUTICS REGAINS FULL RIGHTS TO FIN-524 AND
FIN-525
TARGETED MICROBIOME PRODUCT CANDIDATES IN DEVELOPMENT FOR IBD
Source text for Eikon: ID:nGNXfyTDF
Further company coverage: FNCH.O
Recent news on Finch Therapeutics
See all newsFinch wins US jury trial against Ferring over fecal-transplant patents
Brief: Finch Therapeutics Group Received A Notice From Nasdaq Acknowledging Fact That Co Does Not Meet Requirements Of Rules On April 2
Brief: Finch Therapeutics Got Letter From Nasdaq That Co Has Regained Compliance With Nasdaq’s Listing Rule 5450(A)(1)
U.S. STOCKS ON THE MOVE-Gold miners, ImmunoGen, Oracle
U.S. STOCKS ON THE MOVE-Teekay, gold miners, Oil-Dri Corp